Abstract
This chapter reviews reports of experiments conducted to study transfer factor (TF) therapy in disseminated neoplasms. It is stated that TF was employed in patients with disseminated neoplasms to potentiate or induce cell-mediated immunity (CMI) of the delayed type against neoplastic antigens. The reports reveal that nine patients with malignant melanoma and one patient each with breast carcinoma, bronchogenic carcinoma, vulvar squamous carcinoma, ovarian carcinoma and disseminated thymoma to the pleura with secondary mucocutaneous candidiasis (MC) were studied. Local inflammatory changes in the tumor were recorded on two occasions each in patients with breast carcinoma and with vulvar DN. The results suggested that data is accumulating in experimental animals and humans that indicate that CMI responses are important events in controlling neoplastic proliferation. Dialyzable TF therapy was not observed to cause any significant regression in our nine patients with malignant melanoma. Results also stated that limited clinical responses occurred with TF obtained from family members or donors with tumors in remission. This implies that there may be qualitative differences in TF for DNs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
